Plasmacytoid Dendritic Cell Infiltration in Acute Myeloid Leukemia

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• Plasmacytoid dendritic cells (PDCs) are implicated in tumorigenesis and progression within the tumor microenvironment (TME).
• PDC infiltration is observed in various hematologic malignancies.
• The clinical significance of PDCs in acute myeloid leukemia (AML) requires further investigation.

Purpose of the Study:

• To evaluate the clinical significance of plasmacytoid dendritic cell (PDC) infiltration in acute myeloid leukemia (AML).
• To assess the association between PDC frequency and clinical outcomes in AML patients.
• To explore the potential role of PDCs in AML pathogenesis.

Main Methods:

• Flow cytometry was used to determine PDC frequency in 80 acute myelomonocytic leukemia (AML-M4) and 83 acute monocytic leukemia (AML-M5) patients.
• Clinical data, including bone marrow blasts, Hb concentration, white blood cell and platelet counts, chemotherapy cycles for complete remission (CR), and survival times, were analyzed.
• Drug sensitivity to standard chemotherapy regimens was assessed in relation to PDC infiltration.

Main Results:

• PDC infiltration was identified in 62 cases.
• Patients with PDC infiltration exhibited higher bone marrow blasts, higher mean Hb, and required more chemotherapy cycles for CR.
• PDC-infiltrated patients showed lower white blood cell and platelet counts, reduced sensitivity to chemotherapy, and shorter overall survival (OS) and progression-free survival (PFS).

Conclusions:

• PDC infiltration serves as a prognostic marker for risk stratification in AML-M4/M5.
• PDCs may undergo transdifferentiation into leukemia cells within the AML microenvironment.
• These findings highlight the critical role of PDCs in AML progression and treatment response.